| Literature DB >> 31963176 |
Yong Han1,2, Yan Wang3, Yuehan Yang2, Haotong Chen2.
Abstract
Four novel bioactive tetrahydroanthra-γ-pyrone compounds, shellmycin A-D (1-4), were isolated from the marine Streptomyces sp. shell-016 derived from a shell sediment sample collected from Binzhou Shell Dike Island and Wetland National Nature Reserve, China. The structures of these four compounds were established by interpretation of 1D and 2D NMR and HR-MS data, in which the absolute configuration of 1 was confirmed by single crystal X-ray diffraction, and compound 3 and 4 are a pair of stereoisomers. Compound 1-4 exhibited cytotoxic activity against five cancer cell lines with the IC50 value from 0.69 μM to 26.3 μM. Based on their structure-activity relationship, the putative biosynthetic pathways of these four compounds were also discussed.Entities:
Keywords: NMR and single crystal X-ray diffraction; cytotoxic activity; marine Streptomyces sp.; shell-016; stereoisomers; tetrahydroanthra-γ-pyrone
Year: 2020 PMID: 31963176 PMCID: PMC7024178 DOI: 10.3390/md18010058
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–4.
NMR spectroscopy data (MeOD-d4) for compound 1.
| Pos. | δH (mult., | δc | 1H-1H COSY | HMBC |
|---|---|---|---|---|
| 2 | 174.9s | |||
| 3 | 6.73 (s) | 111.6d | C-14, C-2, C-4, C-4a | |
| 4 | 182.1s | |||
| 4a | 120.6s | |||
| 5 | 138.0s | |||
| 6 | 7.47 (s) | 129.9d | C-13, C-12a, C-7, C-4a, C-6a | |
| 6a | 142.6s | |||
| 7 | 7.43 (s) | 117.4d | C-8, C-6, C-11a, C-6a, C-11 | |
| 7a | 147.8s | |||
| 8 | 4.95 (dd, 7.5, 3.8) | 69.0d | H-9 | C-10, C-7, C-7a |
| 9 | 2.18, 2.37 (m) | 32.7t | H-8, H-10 | C-10, C-8, C-7a, C-11 |
| 10 | 2.81, 3.00 (dq, 17.6, 4.6) | 36.8t | H-9 | C-9, C-8, C-11 |
| 11 | 207.0s | |||
| 11a | 113.3s | |||
| 12 | 165.8s | |||
| 12a | 114.7s | |||
| 12b | 159.1s | |||
| 13 | 4.16,4.26 (m) | 42.9t | C-13-COOH, C-5, C-4a, C-6 | |
| 13-COOH | 175.7s | |||
| 14 | 78.1s | |||
| 15 | 1.55 (s) | 24.0q | C-3, C-2, C-16 | |
| 16 | 5.28 (d, 10.5) | 71.5d | H-17 | C-3, C-2, C-15 |
| 17 | 5.73 (ddd, 11.7, 10.5, 1.5) | 130.0d | H-16, H-18 | C-19, C-16, C-14 |
| 18 | 5.88 (dq, 11.7, 6.8) | 130.1d | H-17, H-19 | C-19, C-16 |
| 19 | 1.92 (dd, 6.9, 1.8) | 14.4q | H-18 | C-17, C-16 |
Figure 2Selected 1H–1H COSY, HMBC and NOESY correlations for shellmycin A (1).
Figure 3ORTEP drawing of shellmycin A (1).
NMR spectroscopy data (MeOD-d4) for compound 2.
| Pos. | δH (mult., | δc | 1H-1H COSY | HMBC |
|---|---|---|---|---|
| 2 | 174.9s | |||
| 3 | 6.72 (s) | 111.6d | C-14, C-4a, C-2 | |
| 4 | 182.5s | |||
| 4a | 121.1s | |||
| 5 | 138.4s | |||
| 6 | 7.59 (s) | 130.3d | C-13, C-4a, C-7, C-12a | |
| 6a | 143.0s | |||
| 7 | 7.54 (s) | 117.7d | C-8, C-11a, C-6, C-6a | |
| 7a | 148.3s | |||
| 8 | 5.00 (dd, 8.6, 3.9) | 69.3d | H-9 | |
| 9 | 2.21, 2.40 (m) | 33.0t | H-8, H-10 | |
| 10 | 2.87, 3.04 (m) | 37.0t | H-9 | |
| 11 | 207.3 | |||
| 11a | 113.7s | |||
| 12 | 166.2s | |||
| 12a | 115.3s | |||
| 12b | 159.7s | |||
| 13 | 4.26-4.33 (m) | 43.3t | C-13-COOH, C-4a, C-6, C-5 | |
| 13-COOH | 176.2s | |||
| 14 | 78.5s | |||
| 15 | 1.65 (s) | 24.2q | C-3, C-2, C-16 | |
| 16 | 4.19 (dd, 10.2, 1.8) | 76.7d | H-17 | |
| 17 | 1.58, 1.69 (m) | 34.3t | H-16, H-18 | |
| 18 | 1.47, 1.68 (m) | 21.3t | H-17, H-19 | |
| 19 | 1.02 (t, 6.9, 1.8) | 15.1q | H-18 | C-17, C-16, C-14 |
Figure 4Selected 1H–1H COSY, HMBC, and NOESY correlations for shellmycin B (2).
Figure 5Comparison of the experimental ECD spectra of 1 and 2.
NMR spectroscopy data (MeOD-d4) for compound 3.
| Pos. | δH (mult., | δc | 1H-1H COSY | HMBC |
|---|---|---|---|---|
| 2 | 174.8s | |||
| 3 | 6.67 (s) | 109.8d | C-14, C-4a, C-2 | |
| 4 | 182.6s | |||
| 4a | 121.0s | |||
| 5 | 138.3s | |||
| 6 | 7.58 (s) | 130.4d | C-13, C-4a, C-7, C-12a | |
| 6a | 143.0s | |||
| 7 | 7.54 (s) | 117.6d | C-8, C-11a, C-6, C-6a | |
| 7a | 148.4s | |||
| 8 | 5.00 (dd, 8.7, 4.0) | 69.4d | H-9 | C-7, C-7a |
| 9 | 2.21, 2.40 (m) | 33.1t | H-8, H-10 | |
| 10 | 2.87, 3.04 (m) | 37.1t | H-9 | C-8, C-9 |
| 11 | 207.2s | |||
| 11a | 113.8s | |||
| 12 | 166.2s | |||
| 12a | 115.1s | |||
| 12b | 159.7s | |||
| 13 | 4.28 (m) | 43.3t | C-13-COOH, C-4a, C-6, C-5 | |
| 13-COOH | 176.1s | |||
| 14 | 74.8s | |||
| 15 | 1.82 (s) | 28.2q | C-17, C-2, C-14 | |
| 16 | 6.25 (dd, 15.5, 1.3) | 133.9d | H-17 | C-14, C-18 |
| 17 | 6.05 (dd, 15.5, 5.8) | 136.3d | H-16, H-18 | C-14, C-18 |
| 18 | 4.32 (m) | 69.5d | H-17, H-19 | C-16 |
| 19 | 1.26 (t, 6.9, 1.8) | 24.4q | H-18 | C-17, C-18 |
NMR spectroscopy data (MeOD-d4) for compound 4.
| Pos. | δH (mult., | δc | 1H-1H COSY | HMBC |
|---|---|---|---|---|
| 2 | 174.9s | |||
| 3 | 6.67 (s) | 109.8d | C-14, C-4a, C-2 | |
| 4 | 182.6s | |||
| 4a | 121.0s | |||
| 5 | 138.3s | |||
| 6 | 7.57 (s) | 130.4d | C-13, C-4a, C-7, C-12a | |
| 6a | 143.0s | |||
| 7 | 7.53 (s) | 117.6d | C-8, C-11a, C-6, C-6a | |
| 7a | 148.4s | |||
| 8 | 5.00 (dd, 8.7, 4.0) | 69.4d | H-9 | C-7, C-7a |
| 9 | 2.21, 2.40 (m) | 33.1t | H-8, H-10 | |
| 10 | 2.87, 3.04 (m) | 37.1t | H-9 | C-8, C-9 |
| 11 | 207.2s | |||
| 11a | 113.8s | |||
| 12 | 166.2s | |||
| 12a | 115.1s | |||
| 12b | 159.6s | |||
| 13 | 4.24-4.31 (m) | 43.3t | C-13-COOH, C-4a, C-6, C-5 | |
| 13-COOH | 176.1s | |||
| 14 | 74.9s | |||
| 15 | 1.82 (s) | 28.3q | C-17, C-2, C-14 | |
| 16 | 6.26 (d, 15.5) | 133.8d | H-17 | C-14, C-18 |
| 17 | 6.05 (dd, 15.5, 5.6) | 136.2d | H-16, H-18 | C-14, C-18 |
| 18 | 4.33 (m) | 69.4d | H-17, H-19 | C-16 |
| 19 | 1.25 (t, 6.9, 1.8) | 24.4q | H-18 | C-17, C-18 |
Figure 6Selected 1H–1H COSY and HMBC correlations for shellmycin C (3) and shellmycin D (4).
Figure 7Comparison of the experimental and calculated ECD spectra of 3 and 4.
Anti-microbial activity (MIC µg/mL) of compounds 1–4.
| Pathogen Strains | MIC (µg/mL) | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| >100 | >100 | >100 | >100 | |
| 3 | 21 | 46 | 16 | |
| 6 | 13 | 36 | 21 | |
| 11 | 26 | 32 | 21 | |
| >100 | >100 | >100 | >100 | |
| >100 | >100 | >100 | >100 | |
Inhibitory concentration (IC50, µM) of compounds 1–4 against various tumor cell lines (cis-platinum as positive control).
| Compound | IC50 (µM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A375 | H1299 | HepG2 | HT29 | HCC1937 | ||||||
| 24 h | 72 h | 24 h | 72 h | 24 h | 72 h | 24 h | 72 h | 24 h | 72 h | |
|
| 5.22 | 0.69 | 8.63 | 1.32 | 4.22 | 0.89 | 4.69 | 0.85 | 9.68 | 2.62 |
|
| 7.18 | 0.95 | 10.3 | 2.62 | 5.67 | 1.35 | 6.12 | 1.12 | 11.6 | 3.11 |
|
| 40.3 | 11.3 | >50 | 26.3 | 11.3 | 5.03 | 13.0 | 4.33 | >50 | 12.6 |
|
| 6.04 | 0.78 | 10.1 | 2.15 | 5.16 | 1.11 | 5.37 | 1.02 | 10.3 | 2.89 |
| 23.1 | 9.32 | 21.2 | 7.3 | >50 | 18.9 | >50 | >50 | >50 | >50 | |
Figure 8Proposed biosynthetic pathway.